Kyrre Emblem's research group: MRI Research & Technology

Kyrre EmblemGroup leader
Kyrre Emblem
Group leader

One of the major challenges in the treatment of diseases like cancer is that we do not know who will benefit from a particular drug. Since only about half the cancer patients who receive a typical anti-cancer drug benefit and the others just suffer side effects, knowing whether or not a patient's tumor is responding to a drug can bring us one step closer to truly personalized medicine – tailoring therapies to the patients who will benefit and not wasting time and resources on treatments that will be ineffective.

For many diseases, promising new treatment options may turn traditional diagnostic biomarkers insufficient because new drug mechanisms produce different imaging responses. The goal of our research is to find predictive and prognostic imaging-based biomarkers for better identification of judicious, patient-specific treatments and by this help to move the field of medicine forward. The main focus of the research group is the development, implementation and processing of advanced MRI (Magnetic Resonance Imaging) to uncover new structural or functional information of disease. This may include tissue perfusion, diffusion, mechanical forces and subsequent changes in vascular and morphologic structure. Our work includes use of artificial intelligence and neural networks.

Active externally funded projects

  • Horizon2020 Marie Skłodowska-Curie Individual Fellowship Grant 844646 (2019-2021)
    GLIOHAB - Multiparametric imaging of glioblastoma tumour heterogeneity for supporting treatment
  • European Research Council (ERC) Starting Grant 758657 (2018-2022)
    ImPRESS - Imaging Perfusion Restrictions from Extracellular Solid Stress
  • The Research Council of Norway FRIPRO Young Researcher Grant 261984 (2017-2021)
    FORCE - Functional imaging Of vascular Restrictions in CancEr
  • South-Eastern Norway Regional Health Authority Extended Career Grant 2017073 (2017-2021)
    FORCE - Functional imaging Of vascular Restrictions in CancEr
  • South-Eastern Norway Regional Health Authority Grant 2016102 (2016-2019)
    TREATMENT - Improved Therapy Response Assessment in Metastatic Brain Tumors
  • The Norwegian Cancer Society Grant 6817564 (2016-2019)
    TREATMENT - Improved Therapy Response Assessment in Metastatic Brain Tumors
  • South-Eastern Norway Regional Health Authority Career Grant 2013069 (2013-2017)
    LOOPS – Mapping the Vessel Architecture of Cancer
  • The Research Council of Norway BEHANDLING Grant 303249 (2020-2024)
    IMAGINE: Imaging molecular mechanisms of angiogenesis in glioma-associated neovasculature

Major international collaborations:

  • Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
  • Dana-Farber Cancer Institute, Boston, MA, USA
  • University of Texas Southwestern Medical Center, Dallas, USA
  • University Medical Center in Groningen, Groningen, Netherlands
  • Heidelberg University, Mannheim, Germany
  • King`s College London, UK
  • Institute Curie Research Center, Paris, France
  • Universitat Politecnica de Valencia, Valencia, Spain